Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938082 | 0.92 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL3943845 | 0.92 | CDK4 (0.49) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL3945127 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DLMNA | |
| SCHEMBL5423128 | 0.79 | MAPK10 (0.54) | PDE4APDE4BPDE4CPDE4DHPGD | |
| SCHEMBL3939056 | 0.76 | KMT2A (0.44) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL3946869 | 0.75 | CDK4 (0.59) | HPGDLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL27637393 | 0.74 | PTGS2 (0.61) | PTGS2PTGS1HPGDLMNANPSR1 | |
| SCHEMBL391623 | 0.72 | CDK4 (0.57) | HPGDLMNANPSR1SMN1; SMN2L3MBTL1 | |
| SCHEMBL6133660 | 0.72 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPTGS2 | |
| SCHEMBL4033295 | 0.72 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PDE4A 3276/4885PDE4B 3496/4885PDE4C 3820/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | PDE4A 3431/4885PDE4B 3535/4885PDE4C 3966/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PDE4A 3278/4885PDE4B 3545/4885PDE4C 3863/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PDE4A 3330/4885PDE4B 3531/4885PDE4C 3923/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PDE4A 3458/4885PDE4B 3740/4885PDE4C 4030/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PDE4A 3330/4885PDE4B 3531/4885PDE4C 3923/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | PDE4A 3330/4885PDE4B 3531/4885PDE4C 3923/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PDE4A 3278/4885PDE4B 3545/4885PDE4C 3863/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | PDE4A 3458/4885PDE4B 3740/4885PDE4C 4030/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | PDE4A 3276/4885PDE4B 3496/4885PDE4C 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.